Last reviewed · How we verify
Prednisolones acetate
Prednisolone acetate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators.
Prednisolone acetate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators. Used for Treatment of uveitis.
At a glance
| Generic name | Prednisolones acetate |
|---|---|
| Also known as | PA |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to glucocorticoid receptors in the cytoplasm, which then translocate to the nucleus and regulate the expression of genes involved in inflammation. This results in a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.
Approved indications
- Treatment of uveitis
Common side effects
- Increased intraocular pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisolones acetate CI brief — competitive landscape report
- Prednisolones acetate updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI